It has been suggested that the combined assessment of natriuretic peptides and CRP may yield incremental prognostic information in the risk stratification of patients with ACS [2,3], and their combined use has been shown to improve long-term risk prediction of mortality in patients with stable coronary heart disease (CHD) [4]. Here, CRP is linked to coronary artery disorder.